QIAGEN/$QGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,700
Headquarters
Website
QIAGEN Metrics
BasicAdvanced
$9.6B
23.27
$1.89
0.68
$0.25
0.57%
Price and volume
Market cap
$9.6B
Beta
0.68
52-week high
$51.88
52-week low
$37.63
Average daily volume
1.1M
Dividend rate
$0.25
Financial strength
Current ratio
2.6
Quick ratio
2.122
Long term debt to equity
44.599
Total debt to equity
58.289
Dividend payout ratio (TTM)
13.38%
Interest coverage (TTM)
24.36%
Profitability
EBITDA (TTM)
1,011.556
Gross margin (TTM)
79.99%
Net profit margin (TTM)
19.58%
Operating margin (TTM)
40.31%
Effective tax rate (TTM)
20.04%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.14%
Return on equity (TTM)
11.29%
Valuation
Price to earnings (TTM)
23.272
Price to revenue (TTM)
4.509
Price to book
2.63
Price to tangible book (TTM)
12.02
Price to free cash flow (TTM)
19.763
Free cash flow yield (TTM)
5.06%
Free cash flow per share (TTM)
2.229
Dividend yield (TTM)
0.57%
Forward dividend yield
0.57%
Growth
Revenue change (TTM)
5.32%
Earnings per share change (TTM)
343.86%
3-year revenue growth (CAGR)
-2.38%
10-year revenue growth (CAGR)
4.82%
3-year earnings per share growth (CAGR)
-5.44%
10-year earnings per share growth (CAGR)
14.86%
Bulls say / Bears say
Qiagen’s net sales increased 5% year-over-year (7% at constant exchange rates) to $483.46 million in Q1 2025, beating analyst estimates of $476.78 million. Adjusted EPS came in at $0.55, ahead of the consensus forecast of $0.51 (Nasdaq).
After outperforming in Q1, Qiagen lifted its full-year 2025 guidance for adjusted EPS to approximately $2.35 at constant exchange rates, up from the previous outlook of $2.28, signaling greater confidence in its primary growth areas (Nasdaq).
Qiagen posted 7% net sales growth year-over-year to $534 million in Q2 2025. Adjusted diluted EPS was $0.60, and the company increased its full-year net sales growth projection to 4–5% at constant exchange rates, highlighting ongoing operational strength (RTTNews).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
QIAGEN News
AllArticlesVideos
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
Business Wire2 days ago
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
Business Wire2 days ago
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $9.6B as of November 06, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 23.27 as of November 06, 2025.
Does QIAGEN stock pay dividends?
Yes, the QIAGEN (QGEN) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $0.25 and the yield is 0.57%. QIAGEN has a payout ratio of 13.38% on a trailing twelve-month basis.
When is the next QIAGEN dividend payment date?
The next QIAGEN (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.